title: The impact of serotonergic stimulation on reelin and glutamate decarboxylase gene expression in adult female rats.
abstract: BACKGROUND
  Reelin plays an important role in the regulation of synaptic plasticity in adulthood. Administration of 5-metoxytryptamine (5MT), an agonist of serotonin receptors, during natal and neonatal periods results in decreased reelin expression. In adulthood, reelin is expressed by GABAergic neurons.
  
  
  OBJECTIVE
  The purpose of this study was to reveal the effect of elevated serotonergic stimulation on the expression of reelin and glutamate decarboxylase (GAD1) in adulthood as well as on depressive behavior and spatial cognitive abilities in adult female rats.
  
  
  METHODS
  Rats were injected with 5MT. A forced swimming test was used for evaluation of the depressive behavior and Morris water maze test was used for evaluation of spatial cognition. Brains were used for measuring the expression of reelin and GAD1.
  
  
  RESULTS
  We found a significant decrease in reelin expression in the cerebellum and prefrontal cortex of 5MT-treated rats. GAD1 expression was decreased in the cerebellum of 5MT-treated rats. 5MT-treated rats reached a lower immobility score in the forced swimming test. The Morris water maze test did not reveal any significant differences.
  
  
  CONCLUSIONS
  We have shown that administration of serotonin receptor agonist resulted in a decreased RELN and GAD1 expression in the cerebellum of adult female rats. We propose that this phenomenon might be relevant in the pathogenesis of autism (Fig. 3, Ref. 38). Full Text in free PDF www.bmj.sk.
authors: Comenius University in Bratislava, Faculty of Medicine, Institute of Physiology, Slovakia. silvia.lakatosova@gmail.com
authors: S
authors: S
authors: Lakatosova
authors: P
authors: P
authors: Celec
authors: E
authors: E
authors: Schmidtova
authors: A
authors: A
authors: Kubranska
authors: J
authors: J
authors: Durdiakova
authors: D
authors: D
authors: Ostatnikova
mesh_terms: D008735:5-Methoxytryptamine / Q000494:pharmacology*; D000818:Animals; D001321:Autistic Disorder / Q000235:genetics; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000378:metabolism*; D015816:Cell Adhesion Molecules, Neuronal / Q000235:genetics* / Q000378:metabolism; D016326:Extracellular Matrix Proteins / Q000235:genetics* / Q000378:metabolism; D005260:Female; D015870:Gene Expression / Q000187:drug effects*; D005968:Glutamate Decarboxylase / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D009419:Nerve Tissue Proteins / Q000235:genetics* / Q000378:metabolism; D051381:Rats; D000091042:Reelin Protein; D012697:Serine Endopeptidases / Q000235:genetics* / Q000378:metabolism; D018490:Serotonin Agents / Q000494:pharmacology*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology
chemical_list: D015816:Cell Adhesion Molecules, Neuronal; D016326:Extracellular Matrix Proteins; D009419:Nerve Tissue Proteins; D000091042:Reelin Protein; C000717129:Reln protein, rat; D018490:Serotonin Agents; D017366:Serotonin Receptor Agonists; D008735:5-Methoxytryptamine; C000717127:RELN protein, human; D012697:Serine Endopeptidases; D005968:Glutamate Decarboxylase